The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Pediatrics. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Tue, 28 Jul 2026 20:00:40 GMT 2026 NEJM Group en-us 1440 The Trump administration’s legal theories about gender-affirming care, if accepted, could shift the equilibrium of medical decision making in the United States in important ways. https://www.nejm.org/doi/full/10.1056/NEJMp2605975?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2605975 Benjamin A. Barsky, Brendan Reid, Christopher Robertson 2026-07-25 Medical Standards by Federal Fiat In this trial, among adolescents with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor mavacamten led to a significantly greater reduction in left ventricular outflow tract obstruction than placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2601103?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601103 Joseph W. Rossano, Charles Canter, Cordula M. Wolf, Andrew Papez, Marta Gambra, Randall M. Bryant, Juan Alejos, Michael McCulloch, Georgia Sarquella Brugada, Matthew J. Bock, Aamir Jeewa, F. Bennett Pearce, Milind Y. Desai, Nicholas Favatella, Atefeh Javidialsaadi, Van Phung, Thomas Rano, Lin Zhu, Joshua L. Dyme, Seema Mital, the SCOUT-HCM Investigators* 2026-07-23 Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy In a patient with Duchenne muscular dystrophy, cardiotoxic effects developed after treatment with delandistrogene moxeparvovec. Microdystrophin levels in the heart and skeletal muscle were less than 1% of normal dystrophin levels. https://www.nejm.org/doi/full/10.1056/NEJMc2518477?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2518477 Benjamin J. Samelson-Jones, Cristina Martos-Rus, Carolyn M. Yrigollen, Luis Tecedor, Juliana C. Small, Susan E. Matesanz, Connor T. Watson, Andrew R. Vanden Heuvel, Sean Carrig, Sabrina W. Yum, John F. Brandsema, Kimberly Lin, Carol Wittlieb-Weber, Angela N. Viaene, Pierre P. Russo, Sara Partington, Katie Huynh, Tiffany Seneviratne, Silvia Juarez Rojas, Bhavya S. Doshi, Perry Shieh, Kevin M. Flanigan, Emma Frair, Stefan Nicolau, Michael W. Lawlor, Julie M. Crudele, Beverly L. Davidson, Lindsey A. George 2026-07-22 Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD Fibromyalgia is associated with widespread pain, sleep difficulty, fatigue, and cognitive symptoms. Treatment includes education and nonpharmacologic interventions; selected drugs may help, but opioid agents are not recommended. https://www.nejm.org/doi/full/10.1056/NEJMcp2411656?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2411656 David A. Williams, Daniel J. Clauw 2026-07-16 Fibromyalgia Medication management in autism requires clinicians to navigate uncertainty while respecting the experiences of autistic people and their families. Shared decision making can be a helpful approach. https://www.nejm.org/doi/full/10.1056/NEJMp2602649?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2602649 Yaara Zisman-Ilani, Ron Walfisch, Jeremy Veenstra-VanderWeele, David S. Mandell 2026-07-16 Pharmacotherapeutic Decisions in Autism A 6-month-old baby boy was transferred to a quaternary children’s hospital for seizures. A radiograph of a hand and wrist showed dense, transverse bands of metaphyseal sclerosis in the radius, ulna, metacarpals, and phalanges. https://www.nejm.org/doi/full/10.1056/NEJMicm2603074?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2603074 Jason Haines, Tony Huynh 2026-07-16 Lead Lines in Severe Lead Poisoning Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2512275?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2512275 Jennifer L. Miller, Hanneke M. van Santen, Susan A. Phillips, Jill Hamilton, Jens Aberle, Thozhukat Sathyapalan, Zainaba Mohamed, Shana E. McCormack, Ashley H. Shoemaker, Megan M. Kelsey, Luma Ghalib, Guenter Stalla, Vidhu V. Thaker, Reema Habiby, Katie Larson Ode, Martin Wabitsch, Mehul Dattani, M. Jennifer Abuzzahab, Hussein Abdullatif, Ryan Morgan, Margaret Stefater-Richards, Vanita R. Aroda, Carsten Friedrich, Joan C. Han, Hiraku Ono, Keisuke Nagasaki, Tomohiro Tanaka, Tsuyoshi Isojima, Hiroshi Arima, Cecilia Scimia, Guojun Yuan, Hermann L. Müller, Christian L. Roth, the TRANSCEND Trial Group* 2026-07-09 Setmelanotide for the Treatment of Acquired Hypothalamic Obesity The author describes the scientific basis for a trial of an MC4R agonist in persons with acquired hypothalamic obesity. Those who received the drug had reductions in body-mass index and hunger. https://www.nejm.org/doi/full/10.1056/NEJMe2606217?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606217 I. Sadaf Farooqi 2026-07-09 Science behind the Study: Treating Acquired Hypothalamic Obesity A 4-year-old boy presented to the ED with a 1-hour history of leg pain and an inability to bear weight on the left side after jumping on a trampoline. Radiographs showed a nondisplaced fracture of the proximal tibial metaphysis. https://www.nejm.org/doi/full/10.1056/NEJMicm2601744?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2601744 Tushar Kumar, Sakura M. Noda 2026-07-02 Trampoline Fracture This artificial intelligence–derived and validated machine-learning system appeared to predict the risk of Hirschsprung disease with the use of genetic and demographic data from participants in China. https://www.nejm.org/doi/full/10.1056/NEJMc2401139?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2401139 Yang Wang, Xingjie Hao, Zhonghua Yang, Allan M. Goldstein 2026-07-02 Artificial Intelligence and Detection of Hirschsprung Disease In this phase 3, randomized trial involving children with achondroplasia (3 to 17 years of age), once-daily oral infigratinib for 1 year significantly increased the annualized height velocity as compared with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2604565?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604565 Ravi Savarirayan, Julie Hoover-Fong, Melita Irving, Paul Arundel, Josep Maria de Bergua, Philippe M. Campeau, Toby Candler, Benjamin T. Cocanougher, Valerie Cormier-Daire, Thomas Edouard, Svein O. Fredwall, Paul Harmatz, Daniel Hoernschemeyer, Henrik U. Irgens, Saumya Jamuar, Peter Kannu, Janet M. Legare, Antonio Leiva-Gea, Helen McDevitt, Roberta Onesimo, John Phillips III, Mariana del Pino, Marie-Eve Robinson, Massimiliano Rossi, Mars Skae, Leanne M. Ward, Klane K. White, Jane Schmidt, Ted Lystig, Ariana Salvatici, Yun Bai, Peter W. Butler, David van Veenhuyzen, Daniela Rogoff 2026-06-28 Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia Peanuts should be introduced at 4 to 6 months of age in infants at high risk for allergy and at approximately 6 months of age in other infants. For infants with peanut allergy, early immunotherapy is safer and more effective. https://www.nejm.org/doi/full/10.1056/NEJMcp2314424?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2314424 George Du Toit, Gideon Lack 2026-06-25 Prevention and Treatment of Peanut Allergy A 5-month-old full-term boy was brought to the clinic with a 3-week history of rash. The baby was irritable, with sparse hair, pitting edema of the limbs, and desquamation of hyperpigmented patches on the limbs and trunk. https://www.nejm.org/doi/full/10.1056/NEJMicm2602658?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2602658 Jashir Ahammed Kolathil, Gadhiraju Manisha Varma 2026-06-25 Kwashiorkor Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications. https://www.nejm.org/doi/full/10.1056/NEJMp2601256?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601256 Robert D. Brook, Sanjay Rajagopalan 2026-06-25 Improving Global Air-Quality Indices — The WHO’s New Roadmap The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. https://www.nejm.org/doi/full/10.1056/NEJMp2601300?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601300 Arianne Teherani, Rupa Basu, Sheri Weiser 2026-06-25 When Health Costs No Longer Count — Air Pollution and EPA Rulemaking Spatial analysis in South Carolina revealed that measles infections were clustered in areas where public school vaccination rates were lower. https://www.nejm.org/doi/full/10.1056/NEJMc2604004?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604004 Emily A. Serman, Brian Witrick, Lior Rennert 2026-06-25 Clusters of Concern — Spatial Link between Childhood Undervaccination and Measles Outbreaks in South Carolina A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing. https://www.nejm.org/doi/full/10.1056/NEJMc2518422?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2518422 Shampavi Sri Haran, Lucy Cain, Artur Darmanian, Michael Krivanek, Dale Wright, Wayne Nicholls, Martin Lowe, Luciano Dalla-Pozza, Bruce Goodwin, Jane McEniery, Kevin Hardin, Ashleigh Sullivan, Natacha Omer 2026-06-25 Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. https://www.nejm.org/doi/full/10.1056/NEJMra2416814?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2416814 Laszlo Hegedüs, Lori J. Wirth, R. Michael Tuttle 2026-06-18 Management of Differentiated Thyroid Cancer Observations in Down syndrome were critical to Alzheimer’s disease discoveries. But persons with Down syndrome have historically been excluded from trials relying on insights derived from their biology. https://www.nejm.org/doi/full/10.1056/NEJMp2602106?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2602106 Michael S. Rafii 2026-06-18 The Convergence of Down Syndrome and Alzheimer’s Disease — Scientific and Ethical Imperatives In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. https://www.nejm.org/doi/full/10.1056/NEJMc2517274?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2517274 Kathryn Maitland, Maurice Okao, Melissa D. Conrad, Tonny Etwop, Modester Akite, Emmanuel Oguda, Florence Alaroker, Denis Aromut, Rita Muhindo, Sophie Uyoga, Peter Olupot-Olupot, Christabel Mogaka, Roisin Connon, Thomas Katairo, Martin Okitwi, Jessica Briggs, Diana M. Gibb, Nicholas P.J. Day, Nicholas J. White, Thomas N. Williams, Arjen M. Dondorp, A. Sarah Walker, Elizabeth C. George, Philip J. Rosenthal, for the SMAART-CHARISMA group† 2026-06-18 Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda